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Abstract
Cardiovascular diseases (CVDs) have been reported to have a complex  
pathogenesis by a number of studies. Atherosclerosis and inflammation have been 
established as the main contributors to CVDs. Furthermore, genetic polymor-
phisms have been identified and found to have a correlation with an individual’s 
susceptibility to developing CVD. Some of these polymorphisms and corresponding 
cardiovascular risk (CVR) factors include: C174G (Interleukin (IL)-6 association), 
methylenetetrahydrofolate reductase (MTHFR) C667T/A1298C (hyperhomocyste-
inaemia), VII R353Q (coagulation factor VII association) and rs247616/rs1968905/
rs1270922 (cholesteryl ester transfer protein (CEPT) - cholesterol metabolism) 
amongst others. At a time when disease prediction, diagnosis and prognosis are still 
being investigated, these polymorphisms have the potential for use in these areas as 
well as opening more opportunities in the understanding of CVD. The objective of 
this chapter was to review the current knowledge about the relationship between 
genetic polymorphisms and cardiovascular disease.
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1. Introduction
Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and 
blood vessels and include coronary heart disease (CHD), cerebrovascular disease, 
peripheral arterial disease, rheumatic heart disease, congenital heart disease, deep 
vein thrombosis and pulmonary embolism [1]. The pathogenesis of CVD is mainly 
attributed to atherosclerosis which starts with a progressive alteration and deposit of 
plaque in the inner walls of the arteries [2]. It also involves the interaction of blood cells, 
vascular wall, lipoprotein and immune system, leading to the development of CVD [2, 
3]. Atherosclerosis is characterised by arterial wall thickening and a loss of elasticity 
[3]. Atherosclerotic plaque consists of a soft yellow lesion (mostly consisting of lipids) 
and covered with a white fibrous cap [4], resulting in clinically important complica-
tions such as mechanical obstruction of the blood vessel, thrombosis and weakening 
of the underlying endothelial layer leading to aneurysm formation [5]. Atherosclerosis 
has a complicated pathogenesis. It has been reported that both lipoprotein retention 
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and inflammatory cellular components are involved in the development of a plaque. 
It has long been accepted that low-density lipoprotein cholesterol (LDL-C) is a causal 
agent for atherosclerosis. Furthermore, monocytes and foam cells have been associated 
with the advancement of atherosclerotic disease [3, 6, 7]. Alkhalil and Choudhury [6] 
reported that structures outside vascular intima and media are also linked to atheroscle-
rosis. Pathologically the progression of the lesion is as follows: from endothelial injury 
and dysfunction to fatty streak to fibrotic plaque to an eventual complicated lesion [8]. 
Atherosclerosis is thus a multifactorial progressive disorder that clinically manifests 
mostly during middle age or even later in life [8, 9]. Elderly people usually have poor 
endothelial healing with prolonged exposure to various risk factors as well as alterations 
in blood vessels, which increase the probability of a cardiovascular event [8–10].
2. Cardiovascular risk biomarkers
Several genetic and environmental factors have been shown to play a significant 
role in the progression of CVDs [11, 12]. Moreover, there is a close interlink between 
CVD and obesity, dyslipidaemia, oxidative stress, inflammation and hypertension 
to mention a few. Each of these biomarkers have mechanisms and pathways that 
have been reported to directly or indirectly lead to CVD [13]. Every population has 
distinct genetic and ethnic dynamics that contributes to the CVR of the popula-
tion [14, 15]. CVDs are the foremost causes of death worldwide [1], with low and 
middle income countries currently experiencing the highest prevalence and mor-
tality rates [16]. For this reason, recent data suggests that population-based CVR 
profiling is necessary for successful risk determination, disease prevention and 
treatment [1, 14, 15]. The Multinational Monitoring of Trends and Determinants in 
Cardiovascular Disease (MONICA) by WHO [17] and the MORGAM (Monica Risk, 
Genetics, Archiving and Monograph) [18] Project defined a wide range of biomark-





An acute phase protein, a biomarker of the inflammatory reaction and an 
important risk marker for CVD [20]
Interleukin (IL)-6 A pro-inflammatory cytokine, anti-inflammatory myokine and inducer of 
CRP synthesis, associated with increased CVR [21]
Tumour necrosis factor 
(TNF)-α
A pro-inflammatory cytokine that accelerates the progression of CVDs 
[22]




A stromal cell-derived cytokine capable of both pro- and anti-
inflammatory ability linked to CVR [24]
Interleukin (IL)-10 An anti-inflammatory cytokine, stimulating inflammatory resolution and 
deflects endothelial dysfunction [25]
Interleukin (IL)-18 A pro-inflammatory cytokine that stimulates interferon (IFN)-γ 
production and a link to CVR [26]
Neopterin A pteridine that indicates pro-inflammatory immune status, disease 
severity and prognosis in CVD [27]
Dyslipidaemia
Total cholesterol (TC) A sterol organic molecule who’s variability in circulation has been 
associated with a higher risk of CVD [28]
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A type of cholesterol that plays a vital role in plaque formation and 
increased LDL-C levels are correlated with CVR [29]
High-density lipoprotein 
cholesterol (HDL-C)
A lipoprotein that has shown a protective effect on inflammation, 
oxidation, angiogenesis and glucose homeostasis. For this reason, low 
HDL-C levels have been reported to increase CVR [30]
Lipoprotein (a) (Lp-(a)) A protein that carries cholesterol in blood and has demonstrated to be an 
independent and
CVR factor for the advancement of CVD [31]
Apolipoprotein B (Apo B) A structural protein that transports very low-density lipoprotein 
(VLDL-C) and shown as a marker of atherogenic potential and CVR [32]
Apolipoprotein A-I (Apo A-I) A primary component of HDL-C which has been shown to have an 
association with premature CVD [33]
Paraoxonase-1 (PON1) A high-density lipoprotein-associated esterase that has been reported to 
have a direct and an indirect relationship with CVDs [34]
Metabolic biomarkers
Glucose A monosaccharide who’s elevated levels signify diabetes which is 
associated with CVR due to increased atherosclerosis [35]
Insulin A key anabolic hormone of the body. Insulin resistance is exemplified by 
deficiencies in the uptake and oxidation of glucose. The increase in levels 
of insulin have repeatedly been associated with CVD [36]
Haemoglobin A1c (HbA1c) This is a form of haemoglobin that is chemically attached to a sugar 
(glycated haemoglobin). It’s used to diagnose diabetes. Hyperglycaemia is 
associated with CVR [37]
Adiponectin An adipokine with anti-inflammatory and cardiovascular-protective 
properties which can prevent atherosclerosis. Decreased levels of 
adiponectin have been linked to increased CVR [38]
Ferritin A blood protein that stores iron and has been reported as a risk factor for 
CVD [39]
Leptin An adipocyte-derived adipokine that has been demonstrated to stimulate 
oxidative stress, inflammation, thrombosis, arterial stiffness and 
angiogenesis amongst others. These effects lead to the development of 
CVDs [40]
Oxidative stress
Myeloperoxidase (MPO) A cationic protein in neutrophils that stimulates the production of 
oxidants that trigger tissue damage. These oxidation processes contribute 
to atherosclerosis associating increased MPO with CVR [41]
Homocysteine A non-proteinogenic α-amino acid that plays a key role in the synthesis 
of amino acids methionine and cysteine. It has been reported as an 
independent risk factor CVD [42]
Vitamin B12 A coenzyme in the remethylation process of homocysteine. Low levels of 




A cobalamin that transports vitamin B12 into the cells by binding to a 
specific receptor and has been shown to have an association with CVD [44]
Haemostasis
Fibrinogen A protein that is vital for proper blood clot formation. Elevated levels of 
fibrinogen are associated with CVR [45]
Factor VII A protein that produces blood clots in the coagulation cascade. Several 
studies have associated increased factor VII activity with CVR, as it results 





Despite being complex disorders CVDs are preventable. Coronary heart disease, 
hypertonia, and thrombophilia are some examples of these disorders, that have 
been shown to develop from a combination of genetic mutations and environmental 
factors [58, 59]. Fiatal et al., [59] reported that the current advances in the genomics 
of CVDs have created opportunities for the use of predisposition genetic polymor-
phisms for prevention, diagnosis and treatment in the future. Multiple polymor-
phisms (Table 2) have been identified as contributing factors to CVR, namely: 
C174G (IL-6 association) [62], methylenetetrahydrofolate reductase (MTHFR) 
C667T/A1298C (hyperhomocysteinaemia) [131], VII R353Q (coagulation factor VII 
association) [113], rs247616/rs1968905/rs1270922 (cholesteryl ester transfer protein 
Biomarker Description
Factor VIII: von Willebrand 
factor complex
A blood-clotting protein that is also called anti-hemophilic factor. A 
link between increased circulating levels of Factor VIII: von Willebrand 
complex and an increased risk of developing CVD has been reported [47]
Anti-thrombin III & 
D-Dimer
A fibrin breakdown product and marker of activated coagulation that has 
been associated with the advancement of atherothrombosis and eventually 
CVD [48]. Antithrombin III inhibits abnormal blood clot formation. Low 
levels are linked to CVR [49].
Renal function
Creatinine A breakdown product of creatine phosphate from muscle and protein 
metabolism that is measured to assess renal function and is elevated in 
renal damage or failure. Chronic kidney disease and renal failure are 
associated with an increased CVR due to the excess release of renin [50]
Microalbuminuria (MA) A constant elevation of albumin in urine. It signifies endothelial 
dysfunction and is therefore associated with CVR [51]
Cystatin-C A low molecular-weight protein who’s increased circulating concentrations 
appear to have an increased CVR [52]
Necrosis
Troponin 1 A protein found in skeletal and heart (cardiac) muscle fibres that regulate 
muscular contraction. Increased levels Troponin 1 are strongly associated 
with the incidence of CVD [53]
Creatine kinase-MB 
(CK-MB)
An isoenzyme that is found mainly in heart muscle cells. It has been linked 
to hypertension [54]
Other
Vitamin D A secosteroid that increases intestinal absorption of calcium, magnesium 
and phosphate. It controls inflammatory and immune responses (anti-
inflammatory effect). Decreased levels of vitamin D have been associated 
with increased CVR [55]
Folate It’s also known as vitamin B₉ and is involved in the metabolism of 
homocysteine as a coenzyme. A decrease in the levels of folate is hence 
associated with CVR [56]
Intercellular adhesion 
molecule-1 (ICAM-1)
A cell adhesion molecule expressed by several cell types. Increased levels of 
circulating endothelial ICAM-1 are associated with endothelial activation 
and atherosclerosis, therefore increased CVR [57]
Vascular cell adhesion 
molecule (VCAM-1)
A cell adhesion molecule expressed by vascular endothelial cells that has 
been directly associated with the development of CVD [57]
Table 1. 
Classification of CVD risk biomarkers.
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Gene (Homo sapiens) Location Exons Succinct
Inflammatory markers
hs-CRP gene Chromosome 
1: q23.2
3 This gene encodes a pentraxin protein 
which regulates the complement. It’s 
been shown to play a role in a number 
of host defence related functions. The 
concentration of this protein increases 
in reaction to tissue injury, infection, 
or in a cytokine storm inflammatory 
response. Inflammation is involved in 
atherosclerosis and the thinning of blood 
vessels due to the accumulation of lipids. 
This is subsequently associated with CVD 
[60, 61].
IL-6 gene Chromosome 
7: 7p15.3
6 The promotor region of the IL-6 
gene has been the focal point for IL-6 
polymorphism investigations (Hu et 
al., 2018, Ou et al., 2018). This gene 
encodes cytokines that play a role in 
inflammation and the maturation of 
B cells. Furthermore, the resulting 
protein (endogenous pyrogen) has been 
demonstrated to cause a fever in people 
with autoimmune diseases or  
infections (Hu et al., 2018, Ou et al., 2018, 
[62, 63].
TNF-α gene Chromosome 
6: 6p21.33
4 Macrophages produce the 
proinflammatory cytokine encoded by 
this gene. It regulates processes such 
as cell proliferation, apoptosis, lipid 
metabolism, and coagulation by binding 
to receptors TNFRSF1A/TNFR1 and 
TNFRSF1B/TNFBR. It’s been reported in 
conditions such as autoimmune diseases, 
insulin resistance, psoriasis, rheumatoid 
arthritis ankylosing spondylitis, 
tuberculosis, autosomal dominant 
polycystic kidney disease, cancer and 
CVD [64-66].
IL-1 beta gene Chromosome 
2: 2q14.1
7 This gene encodes an interleukin 1 
cytokine protein that is proteolytically 
converted to its active form by caspase 
1 (CASP1/ICE). Activated macrophages 
secrete this protein. The functions and 
link to the development of CVD are 





5 This gene encodes cytokines that 
belong to the gp130 family. These 
cytokines lead to the production of 
multi-subunit receptors which stimulate 
the T-cell-dependent maturation of 
immunoglobulin-producing B cells. It’s 




Gene (Homo sapiens) Location Exons Succinct
IL-10 gene Chromosome 
1: 1q32.1
7 This gene encodes a cytokine that is 
secreted by monocytes and lymphocytes. 
It’s involved in maintaining tissue 
homeostasis and inflammation. 
Additionally, it improves B cell survival, 
proliferation, and antibody production 
[71, 72].
IL-18 gene Chromosome 
11: 11q23.1
6 This gene encodes a proinflammatory 
cytokine that belongs to the IL-1 family. It 
is present as a precursor of macrophages 
and keratinocytes. It functions to regulate 
both innate and acquired immunity. 
It’s been demonstrated in autoimmune, 
inflammatory and infectious diseases 
[73-75].
Neopterin gene The gene expression for NO is stimulated 
by immune cells. For this reason, its 
known as a marker for the activation of 
the immune system. Tetrahydrobiopterin 
is essential for elevated concentrations of 
NOS. It’s been reported to have a protective 
role in in cases of brain damage and 
inflammation [76].
Dyslipidaemia
LDLR gene Chromosome 
19: 19p13.2
18 The low-density lipoprotein receptor 
(LDLR) gene family is made up of proteins 
that are found on the surface of cells 
that play a crucial role in endocytosis. 
After binding to the cell membrane, the 
molecules are taken into the cell where 
metabolism and cholesterol synthesis take 
place (TC, LDL-C, HDL-C). Changes 
in this gene have been linked to the 
development of conditions like familial 
hypercholesterolemia [77-79].
Lp-(a) gene Chromosome 
6: 6q25.3-q26
39 This gene is expressed in the liver. It 
encodes serine proteinase, an enzyme that 
suppresses the tissue-type plasminogen 
activator I activity. The encoded protein 
is involved atherogenesis which produces 
fragments that leads to atherosclerotic 
lesions and promote thrombogenesis. An 
increase in plasma levels of this protein 
has been correlated to atherosclerosis and 
CVD [80-82].
Apo B gene Chromosome 
2: 2p24.1
29 The product of this gene plays a role in 
the metabolism of lipids (chylomicrons, 
LDL, VLDL and triglycerides). It exists in 
two forms, apoB-48 and apoB-100, even 
though they have a common N-terminal 
sequence. This gene and changes in 




hypercholesterolaemia to mention a few 
[83, 63].
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Gene (Homo sapiens) Location Exons Succinct
Apo A-I gene Chromosome 
11: 11q23.3
4 The protein encoded by this gene is Apo 
A-I which forms most of HDL-C in the 
circulation. It functions to enhance the 
transportation of TC from the tissues 
to the liver for excretion. This gene and 
associated mutations have been shown to 
cause conditions such HDL-C deficiencies, 
Tangier disease, and non-neuropathic 
amyloidosis amongst others [84, 85].
PON1 gene Chromosome 
7: 7q21.3
9 The protein encoded by this gene belongs 
to the paraoxonase family and has been 
known to show evidence of lactonase and 
ester hydrolase activity. It is produced 
in the kidney and binds to HDL-C when 
released. CVDs and diabetic retinopathy 
have been linked to this gene and its 
mutations [86, 87].




17 This protein coding gene is located on 
chromosome 16 position 16q13 (H. 
sapiens). It translates a hydrophobic 
glycoprotein that plays a vital role in the 
reversal of cholesterol transport [88], 
[89]. The CETP gene has 17 exons and its 
variants have been studied to assess their 
associations to risks such as CVDs and 
potential benefits as a pharmacological 
agent [90, 91].
Metabolic Biomarkers
GLUT4 gene (SLC2A4) Chromosome 
17: 17p13.1
11 The protein encoded by this gene is 
a glucose transporter. It belongs to 
the solute carrier family 2 (facilitated 
glucose transporter). It regulates how the 
adipocytes and muscles take insulin-
stimulated glucose. A link between this 
gene and diabetes mellitus has been 
demonstrated [92, 93].
INS gene Chromosome 
11: 11p15.5
3 Insulin is encoded by this gene. It 
regulates how carbohydrates and lipids 
are metabolised. It enhances how glucose 
is absorbed into the liver and muscle cells 
after being bound to the insulin receptor 
(INSR). Variants in the sequence of this 
gene have been reported and linked to the 
development of various forms of diabetes 
mellitus [94, 95].
Resistin (RETN) gene Chromosome 
19: 19p13.2
4 The protein encoded by this gene is 
resistin. It belongs to the family of resistin-
like genes with distinct 10 cys identical 
spacing. This hormone is secreted by 
adipocytes and has been known to inhibit 
the ability of insulin to stimulate glucose 
uptake. It has also been linked to obesity 
and type II diabetes [96, 97].
Cardiovascular Risk Factors
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Gene (Homo sapiens) Location Exons Succinct
Adiponectin, C1Q 
And Collagen Domain 




4 This gene encodes a protein that has a 
similar composition to collagens X and 
VIII and complement factor C1q. It’s 
primarily found in adipose tissue. The 
biological processes this gene is involved 
in are metabolic and hormonal processes. 
Adiponectin deficiency has been 
correlated with this gene and its variants 
[98, 99].




4 The ferroxidase enzyme is encoded by 
this gene. It stores iron and is made up of 
24 subunits of the heavy and light ferritin 
chains. Mutations have been reported 
to affect iron transport and secretion 
in tissues. Consequently, this results in 
conditions such as neurodegenerative 
diseases [100, 101].
Leptin (LEP) gene Chromosome 
7: 7q32.1
3 Leptin is encoded by the LEP gene. 
The adipocytes secrete this protein, 
and it is responsible for maintaining 
energy homeostasis after binding to 
leptin receptors. Polymorphisms in this 
gene cause obesity and type 2 diabetes 
mellitus. It’s also been demonstrated in 







12 This gene encodes the haem protein 
MPO. It’s present in polymorphonuclear 
leukocytes where it functions in host 
defences. It secrets hypohalous acids that 
are pivotal to the microbicidal activity of 
neutrophils. Elevated levels of MPO have 





12 This protein facilitates the conversion 
of 5,10-methylenetetrahydrofolate 
to a co-substrate for homocysteine 
remethylation to methionine known 
as 5-methyltetrahydrofolate. The 
physiological functions of MTHFR include 
folate metabolism, DNA methylation and 






9 This gene encodes transcobalamin. This 
protein transports cobalamin belonging 
to the vitamin B12-binding protein family. 
Variations in the TCN2 gene have been 
associated with transcobalamin deficiency 
[109, 110].
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Gene (Homo sapiens) Location Exons Succinct
Haemostasis
Fibrinogen gene
Factor VII gene Chromosome 
13: 13q34
10 It is a coagulation factor VII protein coding 
gene with 10 exons. Despite the variability 
in the findings due to small sample 
populations, various studies have been 
conducted on the R353Q polymorphism, 
factor VII conditions and its association 
to CVD [111-113]. This gene is crucial for 
haemostasis and is transported in circulation 
as a zymogen. It is activated by proteolysis 
which further stimulates the coagulation 
cascade by transforming factor IX to factor 
IXa and/or factor X to factor Xa [114].
Factor VIII gene Chromosome 
X: Xq28
27 This gene encodes a protein that 
participates in blood-clotting (intrinsic 
pathway). It produces two isoforms. 
Isoform 1 (large glycoprotein) links with 
von Willebrand factor in a noncovalent 
complex while variant 2 (small protein) is 
crucial for coagulant activity. Mutations 
in this gene lead to haemophilia A, a 
prevalent recessive X-linked coagulation 
disorder [115, 116].




9 This gene encodes antithrombin III. This 
is a protease inhibitor belonging to the 
serpin superfamily. It participates in the 
blood coagulation cascade by inhibiting 
the activity of certain proteins (heparin). 
Studies have identified variations in this 
gene which result in antithrombin-III 
deficiency which presents a potent risk for 
thrombosis [117, 118].
Renal function
Cystatin 3 (CST3) gene Chromosome 
20: 20p11.21
4 This gene encodes Cystatin-C belonging 
to the cysteine protease inhibitors family. 
There are three classifications of this 
family, namely: type 1 cystatins (stefins), 
type 2 cystatins and the kininogens. 
They regulate various chemical reactions 
by being enzyme blockers. Defects in 
this gene have been linked to amyloid 
angiopathy. The amount of protein that 
is produced in both atherosclerotic and 
aneurysmal aortic lesions is reduced 
confirming its role in CVD [119, 120].
Necrosis
Troponin I3 (TNNI3) gene Chromosome 
19: 19q13.42
8 The protein encoded by this gene is 
Troponin I (TnI) which is exclusively 
found in the cardiac muscle. It’s one of 
the three proteins (TnI, troponin T (TnT) 
and troponin C (TnC)) making up the 
troponin complex of the thin filaments of 
striated muscle. The troponin complex, 
in the presence of calcium, regulate 
the contraction of cardiac muscles. 
Familial hypertrophic cardiomyopathy 
type 7 (CMH7) and familial restrictive 
cardiomyopathy (RCM) are a result of 
variations in this gene. Elevated TnI levels 




(CEPT) - cholesterol metabolism) [132, 133], Angiotensinogen (AGT) M235T 
(hypertension) [134], G308A (pro-inflammatory) [135], A522T (dyslipidaemia) 
[136] and rs9939609 (obesity predisposition) [137]. Most of the studies investigat-
ing genetic polymorphisms associated with CVD in the past 10 years have been 
conducted in populations of different ancestry and ethnicity [58, 59]. Identifying 
populations that are at risk of developing CVDs may assist in developing prevention 
programs which may reduce disease progression. However, there is a paucity of 
information about CVR and genetic polymorphisms [59]. The aim of this chapter 
was thus to review the literature investigating the prevalence of the various CVR 
factors in relation to their genetic polymorphisms.
Gene (Homo sapiens) Location Exons Succinct




8 This gene encodes Creatine Kinase (CK), 
a cytoplasmic enzyme, that plays a role 
in energy homeostasis. CK reversibly 
catalyses the transfer of phosphate 
between Adenosine triphosphate 
(ATP) and various phosphagens like 
creatine phosphate. It’s been reported 
as a significant marker for myocardial 
infarction [123, 124].
Other




12 The vitamin D3 receptor is encoded by 
this gene. This receptor enables normal 
reaction to vitamin D by the body. Vitamin 
D functions to regulate how calcium and 
phosphate are absorbed from the intestines 
into circulation. This is significant for 
normal formation of bones and teeth. 
Changes in this gene are related with type 





7 ICAM-1 is a cell surface glycoprotein 
that is encoded by the ICAM-1 gene. 
It’s a member of the immunoglobulin 
superfamily. Usually found on endothelial 
cells and immune. The concentrations of 
this glycoprotein become elevated once 
cytokines have been stimulated (CD18) 
[127, 128].




9 This gene belongs to the Ig superfamily 
and encodes, VCAM-1, a transmembrane 
glycoprotein. It is produced on 
cytokine-activated endothelium where 
it facilitates leukocyte-endothelial 
cell adhesion and signal transduction. 
VCAM-1 is involved in atherosclerosis 
progression [129, 130].
Table 2. 
Genes controlling the CVR factors.
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4.  Relationship between some common polymorphisms and 
corresponding CVR factors
4.1 Inflammatory markers
4.1.1 C174G polymorphism (IL-6)
The C174G polymorphism is a mutation that triggers a change in the nucleotide 
bases from guanine to cytosine at position 174 in the promoter region of the IL-6 
gene [138, 139]. This is known as a single-nucleotide substitution (SNP) of one base 
for another and has been demonstrated to affect the transcription of IL-6. The find-
ings on the frequency of the highest genotype are conflicting partly due to differ-
ences in the ethnicity of the study populations. Nevertheless, the reported genotypes 
CC, G allele and GG have all been associated with an increase in serum IL-6 levels 
where they induce a transcriptional inflammatory response [62, 139, 140]. This SNP 
influences the physiology of the IL-6 gene resulting in variations of circulating IL-6 
concentrations. Elevated IL-6 levels have been reported in a wide range of inflam-
mation-associated disease states such as CVR, diabetes mellitus risk, rheumatoid 
arthritis, COVID-19, celiac disease and psoriasis to mention a few [62, 138–140].
4.2 Dyslipidaemia
4.2.1 rs247616, rs1968905 and rs1270922 polymorphisms (CETP)
The CETP polymorphisms (rs247616, rs1968905 and rs1270922) are SNPs that 
occur as a result of substitutions in their nucleotide bases [89, 133]. These polymor-
phisms have previously been used to determine the CETP levels in a CVD population 
[133]. Mutations in the CETP gene have been found to cause hyperalphalipoprotein-
aemia 1 (HALP1). Furthermore, it’s also been shown that different variants code 
for distinct isoforms within this gene. This eventually influences the metabolism of 
HDL-C [89]. Reports on the link between the CETP polymorphisms, CVR and the 
concentrations of CETP through LDL-C are inconsistent [89, 132, 133].
4.3 Metabolic biomarkers
4.3.1 Gly972Arg polymorphism
The Gly972Arg polymorphism occurs as a result of a substitution between 
glycine and arginine (GGG ↔ AGG substitutions) in codon 972 (G972R). It has been 
demonstrated that this mutation is involved in the development of type 2 diabetes 
mellitus (type 2 DM) [141]. This is due to the fact that it’s been described to influence 
tyrosine phosphorylation at a specific site of IRS-1 which may lead to the develop-
ment of insulin resistance (IR) and impair insulin secretion [142]. The Gly972Arg 
polymorphism has been investigated in a number of studies and found to have a high 
prevalence in type 2 diabetic subjects and other conditions like obesity [143, 144].
4.4 Oxidative stress
4.4.1 C677T and A1298C polymorphisms (MTHFR)
The MTHFR C677T polymorphism is a SNP where cytosine (C) is replaced with 
thymine (T) at position 677 resulting in the gene to code for valine as opposed to 
Cardiovascular Risk Factors
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alanine at exon 4. The change between alanine and valine nucleotide bases hap-
pens on codon 222 resulting in this polymorphism sometimes being described as 
Ala222Val polymorphism. It has been reported to have the alleles heterozygous 
C677T and homozygous T667T which are mutant, whereas the homozygous C677C 
is a wild type allele [145–149].
The A1298C polymorphism causes a change where glutamate is substituted 
with an alanine at position 429. Each of these genotypes have been shown to 
reduce the MTHFR enzymatic activity resulting in the methyl group to be 
unavailable for attachment to homocysteine in order to generate methionine. 
Hyperhomocysteinaemia has been reported in the development of a number of con-
ditions, for example, CVR, chronic myeloid leukaemia (CML), multiple abortions, 
autism, osteoporosis, multiple sclerosis, psoriasis, and Alzheimer’s disease  
[106, 108, 135, 145, 146].
4.5 Haemostasis
4.5.1 R353Q polymorphism (factor VII)
In the R353Q polymorphism, guanine is substituted with adenine at the 353rd codon 
of the FVII gene. This missense replacement of arginine (R) by glutamine (Q) in this 
polymorphism has been reported to influence the factor VII levels [150]. Individuals 
who carry the Q allele carriers have been shown to have lower levels of Factor VII than 
those who carry the R allele. Nonetheless, the findings on the association between the 
R353 Q polymorphisms and CVR (thrombosis) are inconclusive [151]. Increased levels 
of factor VII are linked to thromboembolic disorders risk. A relationship between 
defects in the factor VII gene  and CVD has been reported [114, 150, 151].
5. Conclusion
CVDs having a high prevalence and mortality rate globally need to be continu-
ally studied with the focus being risk prediction, prevention of disease as well as 
improving treatment strategies. This review supplements current evidence on the 
contribution of genetic polymorphisms in the pathophysiology of CVDs. Although 
the data from some of the early studies of these polymorphisms is conflicting, 
mainly because the study populations were small and not diverse enough, there are 
promising results in some of the CVR factors. It is therefore apparent that differ-
ent polymorphisms should be studied in large sample sizes, diverse ethnicities and 
demographics. Genetic polymorphisms should be taken into consideration in the 
assessment of risk profiles for CVDs.
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